The agreement has the potential to provide new cancer drugs for the oncology market.
As part of the agreement, the Institute for Cancer Therapeutics will also continue development work on two of Somanta's preclinical cancer drugs, Alchemix and Prodrax.
The Institute of Cancer Therapeutics is devoted to the design, synthesis and evaluation of anticancer therapies, and has a long-standing history of collaborating with external partners to evaluate anticancer agents for efficacy, pharmacokinetic and pharmacodynamic properties.
“We are building on over 10 years of anticancer agent development in this area and are delighted that Somanta shares our vision as to their potential therapeutic value in tumors resistant to the currently available cancer medicines,” commented Professor Laurence Patterson of the Institute for Cancer Therapeutics.